Scienmag

SEPTEMBER 28, 2020

CIC biomaGUNE researchers have demonstrated the restoring in vivo of the connection between neurons, yielding functional results Credit: Author: Pedro Ramos / CIC biomaGUNE Research conducted by two groups at the Center for Cooperative Research in Biomaterials CIC biomaGUNE and one at SISSA, Scuola Internazionale Superiore di Studi Avanzati (Italy), (..)

In-Vivo 96

In-Vivo Research Engineer Medicine 96

Drug Discovery World

JANUARY 25, 2024

US company Vaxxinity and the University of Central Florida (UCF) have announced plans to work together to advance space medicine research. The post Immunotherapy partnership advances space medicine research appeared first on Drug Discovery World (DDW).

Medicine 52

Medicine Research In-Vivo In-Vitro 52

Medical Xpress

MAY 16, 2023

That was the case when Thilini Gamage was to carry out one of the studies in her doctoral work with Professor Eirik Frengen at the Institute of Clinical Medicine, University of Oslo. They study gene variation and mutations that cause rare genetic diseases. A mutation is a permanent change in the genetic material.

In-Vitro 98

In-Vitro In-Vivo Genetic Disease Genetics 98

Scienmag

AUGUST 12, 2020

Researchers in China have taken the first step towards a new way of treating gastric wounds by using a microrobot combined with the new concept of “in situ in vivo bioprinting” to carry out tissue repair inside the body.

In-Vivo 72

In-Vivo Research Engineer Medicine 72

BioTech 365

MAY 1, 2021

Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases at the Association for Research in Vision and Ophthalmology Annual Meeting Editas Medicine to Present Preclinical Data Demonstrating Advancements … Continue reading →

Gene Editing 40

Gene Editing In-Vivo Genetics Gene 40

BioTech 365

APRIL 8, 2021

Nimbus Therapeutics Presents In Vivo Data Showing Single-Agent and Combination Activity of HPK1 Inhibitor Nimbus Therapeutics Presents In Vivo Data Showing Single-Agent and Combination Activity of HPK1 Inhibitor CAMBRIDGE, Mass.–(BUSINESS

In-Vivo 52

In-Vivo Medicine 52

BioSpace

JULY 6, 2021

This appears to be a second example of CRISPR gene editing inside the body, as opposed to in cell cultures.

Gene Editing 101

Gene Editing In-Vivo Gene Medicine 101

Drug Discovery World

FEBRUARY 16, 2023

Challenges remain with current delivery approaches, and genetic medicines applications have been generally restricted to the liver and ex vivo settings. The post Start-up aims to advance transformative genetic medicines appeared first on Drug Discovery World (DDW).

Genetics 52

Genetics Medicine Gene Editing In-Vivo 52

Drug Discovery World

MARCH 12, 2024

DDW Editor Reece Armstrong speaks to Michael Krogh Jensen , Co-founder and CEO of Biomia, about developing plant-based medicines and what recent investment and support from the Bio Studio programme means for its pipeline. Furthermore, opiate- based medicines are often not effective against neuropathic pain.

Medicine 59

Medicine Production Drugs In-Vivo 59

pharmaphorum

AUGUST 5, 2021

Medicines Discovery Catapult (MDC) today announces the relaunch of radiochemistry at the Wolfson Molecular Imaging Centre (WMIC) in Manchester. The facility, which was closed in 2020, includes the multi-million pound cyclotron, one of only a handful in the UK. ” Find out more about MDCs PET Imaging expertise here.

Medicine 52

Medicine In-Vivo Packaging Packaging 52

pharmaphorum

JANUARY 25, 2022

For example, there is no need for in vivo animal or in vitro pre-clinical or non-clinical studies. The area of digital therapeutics is growing rapidly, and in this piece Ben Hargreaves examines why this is the case, how broadly these therapies can be applied and why investment in the area is mounting. This equated to $21.3

Medicine 109

Medicine In-Vivo In-Vitro Development 109

Pharmaceutical Technology

FEBRUARY 15, 2023

Editas Medicine is one of the most important players concerning innovation surrounding CRISPR nucleases. Developing both in vivo and ex vivo gene editing medicines, Editas Medicine is primarily involved in the haematology and oncology therapy areas.

In-Vivo 162

In-Vivo Genome Genomics Gene Editing 162

Pharmaceutical Technology

FEBRUARY 23, 2023

Moderna has entered a strategic research and development partnership with ElevateBio’s Life Edit Therapeutics to discover and develop new in-vivo mRNA gene editing therapies. Our novel editing systems have the potential to precisely modify gene targets for both in vivo and ex vivo therapeutic development.”

Gene Editing 147

Gene Editing Gene In-Vivo Gene Therapy 147

Drug Discovery World

JANUARY 5, 2024

In non-human primate studies, the therapy has demonstrated effective, durable, and well tolerated in vivo CAR-T cell generation. In non-human primate studies, the therapy has demonstrated effective, durable, and well tolerated in vivo CAR-T cell generation.

In-Vivo 52

In-Vivo Development Licensing Licensing 52

BioSpace

JULY 6, 2022

Mogrify and Astellas have forged a collaboration surrounding in vivo regenerative medicine approaches, while CardiNor inked a distribution deal with IBL-America.

In-Vivo 59

In-Vivo Medicine 59

Pharmaceutical Technology

OCTOBER 25, 2022

For the project, deep datasets and capabilities of Sanofi will be leveraged to potentially transform the practice of medicine using digital data and AI. Under the joint research project, a new research team will be set up at the BioMed X Institute in Heidelberg, Germany.

Development 246

Development Drugs In-Vivo Engineer 246

Drug Discovery World

SEPTEMBER 29, 2023

Immunotherapy has taken centre stage this week, with several announcements relating to regulatory approval, investment and research results for antibody and CAR-T therapies, perhaps most significantly, encouraging early-stage data for the first in vivo CAR-T therapy. The top stories: €27.3M

In-Vivo 52

In-Vivo Drugs Antibody Clinical Trials 52

pharmaphorum

NOVEMBER 18, 2022

Gene-testing specialist Editas Medicine has halted development of its lead clinical programme for congenital eye disorders after it generated lacklustre results in a phase 1/2 trial. The decision seemed to spook investors, and shares in the biotech fell more than 10% after the announcement. 30% of all LCA cases.

Sales 92

Sales Trials In-Vivo Gene Editing 92

pharmaphorum

JULY 5, 2022

Cell therapy specialist Mogrify has struck a deal with Japanese drugmaker Astellas to look at ways to deploy regenerative medicine to treat hearing loss caused by factors such as chronic exposure to loud noises. SNHL is the most common form of hearing loss, account for more than 90% of cases and affecting millions of people worldwide.

In-Vivo 108

In-Vivo Bioinformatics Genetics Licensing 108

Drug Discovery World

APRIL 24, 2024

Andrew Farnum, CEO at Variant Bio, added: “Evotec has established and validated in vitro and in vivo models to accelerate programme timelines and is ideally positioned to advance our fibrosis programme. They have the experience and track record in converting breakthrough science into medicines that matter for patients.”

Development 52

Development In-Vivo In-Vitro Genome 52

Drug Discovery World

DECEMBER 6, 2023

“We are impressed by the unique delivery and editing technologies that Eligo has developed, and we believe this will set the stage for Eligo to forge new paths in the application of in vivo gene-editing technologies.” The investment will fuel pre-IND and IND activities to achieve early human data readouts in a PhIb/IIa clinical trial.

Gene Editing 52

Gene Editing Gene In-Vivo Genetics 52

BioTech 365

OCTOBER 6, 2020

Built by CRISPR leaders including Jennifer Doudna to enable best-in-class in vivo therapeutics that permanently treat the underlying cause of disease Initial $20 million Series A led by Andreessen Horowitz Collaboration with Biogen Inc. focused on development of novel genetic … Continue reading →

Genetics 52

Genetics In-Vivo Engineer Medicine 52

Scienmag

JUNE 23, 2021

Martin Borch Jensen to present new research in the biology of aging at the world’s largest aging research for drug discovery conference Credit: Insilico Medicine Hong Kong Limited Wednesday, June 23, 2021, London — Martin Borch Jensen, PhD.,

In-Vivo 57

In-Vivo Research Drugs Medicine 57

Drug Discovery World

MARCH 7, 2024

Ginkgo is also working with Sensible Biotechnologies to develop an in vivo microbial mRNA manufacturing platform. Additionally, Ginkgo announced the successful completion of a manufacturing optimisation program with Biogen, focused on redefining the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors.

Gene Therapy 52

Gene Therapy RNA Engineer Gene 52

Roots Analysis

FEBRUARY 27, 2024

How is the genome editing market landscape evolving: Currently, there is an evident increase in demand for complex biological therapies (including regenerative medicine products), which has created an urgent need for robust genome editing techniques. The global genome editing market is anticipated to grow at a CAGR of 12.6%

Genome 40

Genome Genomics Gene Gene Editing 40

Scienmag

OCTOBER 6, 2021

Niigata and Tokyo, Japan – Three-dimensional (3D) culturing approaches help probe cancer stem-like cells (CSCs)-associated traits, chemoresistance, and cellular heterogeneity ex vivo.

In-Vivo 77

In-Vivo Medicine 77

Worldwide Clinical Trials

NOVEMBER 27, 2023

Casgevy, the commercial product formerly known as exa-cel, is administered by taking stem cells out of a patient’s bone marrow and editing a gene in the cells in a laboratory, with the modified cells then infused back into the patient after conditioning treatment to prepare the bone marrow. In June 2023, the U.S.

Gene Editing 168

Gene Editing Gene Gene Therapy In-Vivo 168

Drug Discovery World

APRIL 10, 2024

The Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for ECUR-506 makes it the first in vivo gene insertion programme authorised for clinical investigation in infants in the US. The post FDA approves first in vivo gene insertion programme in infants appeared first on Drug Discovery World (DDW).

In-Vivo 80

In-Vivo FDA Approval Gene Gene Editing 80

Pharma Marketing Network

DECEMBER 21, 2020

Almost two decades after the human genome was sequenced, a trickle of new genetic medicines (i.e., those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies.

Genetics 52

Genetics Medicine Gene Therapy Marketing 52

Drug Discovery World

AUGUST 7, 2023

Evox Therapeutics has agreed a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, NY, US. Susmita Sahoo, Associate Professor of Medicine, Cardiology at Icahn Mount Sinai has been exploring the use of exosomes in gene therapy for several years.

Gene Therapy 52

Gene Therapy Gene Research In-Vivo 52

Drug Discovery World

APRIL 8, 2024

Outstanding Achievement Award Pfizer Chairman and CEO Dr Albert Bourla received the 2024 AACR Outstanding Achievement Award for Service to Cancer Science and Medicine on behalf of Pfizer during the Opening Ceremony.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

Pharmaceutical Technology

AUGUST 17, 2022

oRNA molecules have been demonstrated to possess increased stability in vivo compared to linear mRNA and can potentially create more quantities of therapeutic proteins within the body. . These programmes will include therapies and vaccines in infectious disease and oncology areas.

RNA 147

RNA Vaccination Vaccine In-Vivo 147

Drug Discovery World

FEBRUARY 23, 2024

7M to drive commercialisation in cell and gene therapy MIP Discovery has closed a £7 million GBP (~$9 million USD) Series A financing round, which enables the company to refocus its mission on improving the downstream processing of cell and gene therapies (CGTs), to accelerate widespread adoption of these potentially life-changing medicines. . £7M

Gene Therapy 52

Gene Therapy Insulin FDA Approval Drugs 52

Scienmag

JULY 21, 2021

Researchers from the UNIGE and the HUG have used information theory for the first time to monitor in vivo the development of resistance mechanisms to a cancer-targeted therapy. Credit: © R.Merat, Neoplasia 2021; 23 (8): 775-782.

In-Vivo 95

In-Vivo Development Research Medicine 95

Scienmag

JUNE 29, 2021

Oncotarget published “High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC” which reported that the aim of […].

In-Vivo 96

In-Vivo In-Vitro Protein Medicine 96

Pharmaceutical Technology

OCTOBER 14, 2022

The AVATAR AI technology will mimic the tumour microenvironment ex vivo and provide capabilities that support the therapeutic products’ development with improved potency and persistence, as well as reduced cell exhaustion. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Gene Therapy 130

Gene Therapy Gene Development Manufacturing 130

Drug Discovery World

DECEMBER 21, 2022

It covers an article by the same name written for Volume 23, Issue 1 – Winter 2021/22 of DDW.

In-Vivo 52

In-Vivo Drugs Life Science Medicine 52